Clinical Trials Logo

SOX clinical trials

View clinical trials related to SOX.

Filter by:
  • None
  • Page 1

NCT ID: NCT05122091 Recruiting - Gastric Cancer Clinical Trials

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Start date: November 5, 2021
Phase: Phase 2
Study type: Interventional

For locally advanced gastric/gastroesophageal junction adenocarcinoma (cT3/4aN+M0 ), neoadjuvant therapy can downstage T and N stage, improve R0 resection rate, reduce recurrence and metastasis rates, and finally improve the long-term survival. A combination of Fruquintinib and SOX for locally advanced gastric/gastroesophageal junction adenocarcinoma could be a novel therapy. This study intends to evaluate the efficacy of Fruquintinib plus SOX as neoadjuvant therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma.

NCT ID: NCT03192735 Active, not recruiting - Neoadjuvant Therapy Clinical Trials

Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer

Start date: September 1, 2017
Phase: Phase 2
Study type: Interventional

We star a multicentre, one-armed, clinical pilot trial intends to investigate the safety and effectiveness of Apatinib Combined With Oxaliplatin, Gimeracil and Oteracil Porassium Capsules Neoadjuvant Ttherapy for Locally Advanced Gastric Cancer(cT2-4/N+M0)